Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Exclusion Criteria

• •1. Significant renal function (eGFR \< 30ml/min)
• •2. Significant hepatic impairment or ALT/AST elevations beyond X2 upper normal limit or known hepatic failure
• •3. Planned coronary intervention or planed surgical intervention (PCI or CABG)
• •4. Recent (\<30 day) acute coronary syndrome (ACS)
• •5. Hypersensitivity to either of the study drug components
• •6. History of lactic acidosis
• •7. Type 1 diabetes
• •8. Current HbA1c \>9%
• •9. Current Insulin treatment
• •10. Active treatment with GLP-1 or other DPP4i medication
• •11. Inability to comply with study protocol
• •12. Active malignancy other than basal cell carcinoma
• •13. Clinically advanced congestive heart failure - NYHA III-IV
• •14. Severe left ventricular dysfunction (LVEF\<25%)
• •15. Recent heart failure decompensation (\<3 months)
• •16. Chronic inflammation (i.e. inflammatory bowel disease, lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection)
• •17. Pregnancy, lactation or child-bearing potential